Fig. 3From: Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept studyTime courses of predicted change from baseline in A CDR-SB, B ADCOMS, and C ADAS-Cog14 by PET SUVr change from baselineBack to article page